论文部分内容阅读
目的:探讨百令胶囊联合厄贝沙坦对早期糖尿病肾病患者血清IL-18水平的影响。方法:50例早期糖尿病肾病患者随机分为两组,对照组单用厄贝沙坦片150mg,qd;治疗组在此基础上加服百令胶囊1.0g,tid,疗程12周。比较两组糖化血红蛋白、尿白蛋白排泄率(UAER)、血清IL-18等指标的变化。结果:与治疗前比较,两组患者UAER、血清IL-18均有不同程度下降(P<0.05),联合治疗组更为显著(P<0.05)。结论:百令胶囊联合厄贝沙坦对早期糖尿病肾病患者肾脏有保护作用,可降低炎症细胞因子IL-18,辅助治疗糖尿病肾病。
Objective: To investigate the effect of Bailing capsule combined with irbesartan on serum IL-18 in patients with early diabetic nephropathy. Methods: Fifty patients with early diabetic nephropathy were randomly divided into two groups. The control group received only irbesartan 150 mg qd. On the basis of this, the treatment group received Bailing capsule 1.0 g, tid for 12 weeks. Comparison of two groups of glycosylated hemoglobin, urinary albumin excretion rate (UAER), serum IL-18 and other indicators of change. Results: Compared with those before treatment, UAER and IL-18 in serum in both groups decreased to some extent (P <0.05), and more significantly in combination therapy group (P <0.05). Conclusion: Bailing capsule combined with irbesartan has a protective effect on the kidney of patients with early diabetic nephropathy, and can reduce the inflammatory cytokine IL-18, adjuvant treatment of diabetic nephropathy.